AndhraNews.net
Home » Features » Health » Antibiotics

Antibiotics


Antibiotics in News

VIVUS, Inc. Announces Intent to Reacquire U.S. and Canadian Rights for Stendra(R) (Avanafil)
MOUNTAIN VIEW, CA--(Marketwired - December 31, 2015) - VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), announced today that it has been notified by Auxilium Pharmaceuticals, Inc., a subsidiary of Endo International, plc., of Auxilium's intention to return the U.S. and Canadian commercial rights for STENDRA® (Avanafil) to VIVUS

Grass Run Farms(R) Becomes Newest Where Food Comes From, Inc. Brand Partner
Where Food Comes From, Inc. (d.b.a. IMI Global, Inc.) (OTCQB: WFCF), the most trusted resource for independent, third-party verification of food production practices in North America, today announced that Greeley-based Grass Run Farms® has engaged in numerous verification and marketing programs with the Company.

ContraFect Corporation Concludes Phase 1 Study of CF-301
YONKERS, NY--(Marketwired - December 15, 2015) - ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW), a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, today announced the Phase 1, first-in-human study of CF-301 has concluded

Cellceutix Completes Lab Testing of Brilacidin for Planned Phase 3 Trial for Acute Bacterial Skin and Skin Structure Infections

Filgotinib meets primary endpoint in phase 2 study in patients with moderate to severe Crohn's disease
First JAK-inhibitor to show efficacy in Crohn's disease 48% clinical remission rate, statistically significant versus placebo after 10 weeks induction therapy Significant improvements in clinical response and IBDQ quality of life Filgotinib safety profile similar to that previously observed Webcast presentation of the results to be held tomorrow 8 December, 16

Cellceutix Retains Former Durata Executive Ronald Trust as Regulatory Affairs Consultant

Envita Goes Above and Beyond Antibiotics for Recent Chronic Lyme Disease Patient
SCOTTSDALE, AZ--(Marketwired - November 19, 2015) - Envita Medical Center, a Unipathic medical center in Scottsdale, Arizona, appears to have found the missing link when it comes to effective chronic Lyme disease treatment

AIM Exploration Makes Final Preparations to Delivery First Order of Coal
AIM Exploration Inc. (OTCQB: AEXE) Senior Management from AIM Exploration conducted high level operational meetings in Peru earlier this month as the company positions itself to deliver the first shipment of coal to India

AMA Continues Efforts to Combat Antibiotic Resistance
ATLANTA, GA--(Marketwired - November 16, 2015) - With growing concerns over the global public health threat posed by antibiotic resistance, the American Medical Association (AMA) today adopted policy during its Interim meeting to help combat the spread of antibiotic resistant bacteria in all health care facilities

CDC Foundation Partners With The Pew Charitable Trusts to Examine Antibiotic Use in U.S. Healthcare Settings
ATLANTA, GA--(Marketwired - November 16, 2015) - Antibiotic resistance is a growing problem, both in the United States and across the world. The U.S. Centers for Disease Control and Prevention (CDC) estimates that each year in the United States more than 2 million people are infected with antibiotic-resistant organisms, resulting in approximately 23,000 deaths

ContraFect Corporation Announces Third Quarter 2015 Financial and Operating Results
ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW)

Santhera Reports New Data and Updates on Regulatory Filings for Raxone® (idebenone) in Duchenne Muscular Dystrophy (DMD)
Santhera Pharmaceuticals Holding AG /Santhera Reports New Data and Updates on Regulatory Filings for Raxone® (idebenone) in Duchenne Muscular Dystrophy (DMD) . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Cellceutix Files Form 10-Q for Quarter Ended September 30, 2015
BEVERLY, MA--(Marketwired - November 10, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, has filed its quarterly report on Form 10-Q for the quarter ended September 30, 2015 with the Securities and Exchange Commission

VIVUS Reports Third Quarter 2015 Financial Results
MOUNTAIN VIEW, CA--(Marketwired - November 04, 2015) - VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health, today provided a business update and reported its financial results for the third quarter ended September 30, 2015.

Easton Pharmaceuticals Announces It Can Commence Marketing and Sales of Approved Products for Most of Latin American Markets
In parallel with Easton's Focus on Women's Health, Easton Pharmaceuticals (OTC PINK: EAPH) is pleased to announce it can commence the marketing and sales of approved products for most of the Latin American markets. Easton further announces the attendance of the 66th Mexican Congress of Obstetrics & Gynecology in Acapulco being held between November 2 to November 5th.

TiGenix: SEPCELL project in severe sepsis receives €5.4M grant from the EU's Horizon 2020
TiGenix is leading the SEPCELL project which aims to accelerate the clinical development of Cx611 in severe sepsis The €5

Cellceutix Provides Brilacidin Update; New Class of Antibiotics to Enter Phase 3

Cellceutix Announces Date for Annual Meeting
BEVERLY, MA--(Marketwired - October 21, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications today announced that it will hold its 2015 Annual Meeting of Stockholders on Tuesday, December 15, 2015

Hospitals Celebrate Food Day by Serving Meat Raised Without Routine Antibiotics
RESTON, VA--(Marketwired - October 20, 2015) - This week, 270 health care facilities across the country will celebrate Food Day by serving more than 235,000 meals that feature meat and poultry raised without the routine use of non-therapeutic antibiotics

Research Finds Cranberries are an Effective Approach to Help Reduce Antibiotic Use
Business Wire IndiaAn international team of scientists presented new evidence showing how cranberries are poised to be a compelling tool to help reduce antibiotic resistance and oxidative stress.

Cellceutix Adds Dr. Daniel Jorgensen as Chief Medical Officer
Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology and antimicrobial applications, is pleased to announce that Daniel Jorgenson MD, MPH, MBA will join the Cellceutix team as Chief Medical Officer as of January 1, 2015.

ContraFect Receives FDA Approval to Initiate Clinical Trials of CF-301 for MRSA Bloodstream Infections
ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, announced today that the U.S

Swissmedic approves Basilea's antibiotic Zevtera® (ceftobiprole medocaril) for the treatment of pneumonia
Basilea Pharmaceutica AG /Swissmedic approves Basilea's antibiotic Zevtera® (ceftobiprole medocaril) for the treatment of pneumonia . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Galapagos initiates first Phase 1 study in cystic fibrosis and will receive milestone payment from AbbVie
Mechelen, Belgium; 19 December 2014 - Galapagos NV (Euronext: GLPG) announces the initiation of the first Phase 1 study with GLPG1837. This novel potentiator is designed as a CFTR targeted therapy for cystic fibrosis (CF) patients who carry class III/IV mutations (e.g., G551D)

Panera Bread Reports on Progress to Improve Animal Welfare for Poultry and Livestock
ST. LOUIS, MO--(Marketwired - December 17, 2014) - Panera Bread (NASDAQ: PNRA) today offered details regarding responsibly raised livestock and poultry following the company's Food Policy introduction in June

Envita Publishes Important Chronic Lyme Disease Treatment Study
SCOTTSDALE, AZ--(Marketwired - December 16, 2014) - A revealing new study on chronic Lyme disease treatment and the inherent complexities was just published by Dr. Dino Prato and colleagues from Envita Medical Center and featured in the Open Journal Of Medical Microbiology

Galapagos regains full rights to GPR84 inhibitor GLPG1205
Program to enter first Phase 2 patient study in ulcerative colitis this month

Galapagos selects second component of its investigational cystic fibrosis combination treatment

Cellceutix Antibiotic Brilacidin Receives QIDP Designation From FDA
Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to announce that the U.S

Phase III data shows Sandoz' investigational biosimilar filgrastim has similar safety and efficacy as Amgen's NEUPOGEN®
Novartis International AG /Phase III data shows Sandoz' investigational biosimilar filgrastim has similar safety and efficacy as Amgen's NEUPOGEN® . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

ContraFect Submits Complete Response to IND Clinical Hold for CF-301
ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, announced today that it has submitted a complete response to the U.S. Food and Drug Administration (FDA)

Cellceutix: December to Be Momentous Month in Company's History

Galapagos completes recruitment for Darwin 2 monotherapy study with GLPG0634 (filgotinib) in RA
Mechelen, Belgium; 24 November 2014:Galapagos NV (Euronext: GLPG), a clinical stage biotech company focused on developing novel mode of action medicines, announces that recruitment of rheumatoid arthritis (RA) patients for the Darwin 2 study with GLPG0634 has been completed

The Long Island Capital Alliance Showcases Healthcare Companies at Capital Forum
The Long Island Capital Alliance ("LICA"), Long Island's leading non-profit capital formation and business development organization, today announced the successful completion of its Healthcare Capital Forum held on Friday, November 7, 2014

Axxess Pharma Receives Health Canada Approval to Sell High Potency Omega-3 Fish Oil Supplement Throughout Canada
Axxess Pharma Inc. (PINKSHEETS: AXXE), a specialty pharmaceutical and nutritional supplements company, through its wholly owned subsidiary, AllStar Health Brands Inc., is pleased to announce they have now received Health Canada approval to sell their high potency Omega-3 fish oil supplement throughout Canada

Shea Medical Fights Lyme Disease via New Biofilm Treatments
SCOTTSDALE, AZ--(Marketwired - November 17, 2014) - Shea Medical is a boutique medical center specializing in the integrative treatment of Lyme disease and has been treating Lyme disease complex (an advanced form of Lyme disease with co-infections) for years

Galapagos presents clean drug-drug interaction profile with GLPG0634 (filgotinib) at ACR 2014
Mechelen, Belgium 17 November 2014: Galapagos NV (Euronext: GLPG), a clinical stage biotech company focused on developing novel mode of action medicines, announces that it will present data supporting the safe use and absence of drug-drug interactions of GLPG0634 (filgotinib) with drugs commonly prescribed for rheumatoid arthritis (RA) patients

ContraFect Corporation Announces Third Quarter 2014 Results
ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, today announced results for the third quarter ended September 30, 2014. The Company closed its initial public offering (IPO) on August 1, 2014

Galapagos completes recruitment for Darwin 1 study with GLPG0634 (filgotinib) in RA
Mechelen, Belgium 12 November 2014:Galapagos NV (Euronext: GLPG), a clinical stage biotech company focused on developing novel mode of action medicines, announces that recruitment of rheumatoid arthritis (RA) patients for the Darwin 1 Phase 2B study with GLPG0634 has been completed.

Healthcare Experts Across India Come Together to Fight Pneumonia Amongst the Older Population of the Country
To commemorate World Pneumonia Day 2014, experts across renowned national institutes have initiated a campaign to spread maximum awareness about the symptoms and causes of Pneumonia among the elderly population in India. This campaign is an effort to protect adults aged 50 years and above from the deadly pneumococcal disease and thereby reduce the rate of death caused due to pneumonia

CytoSorbents Provides Clinical Update on CytoSorb Dosing Study
CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company working to control inflammation and save lives in the ICU through blood purification with its European Union approved CytoSorb® cytokine filter, provides an end-of-year update on its CytoSorb® Dosing study that is currently ongoing.

Micro Imaging Technology Adds Staph Bacteria to Its Catalog of Identifiers
Micro Imaging Technology, Inc. (OTCQB: MMTC) announced that its MIT 1000 System can now identify the potentially life-threatening bacteria Staphylococcus

Cellceutix Files Orphan Drug Designation Application for Brilacidin for Oral Mucositis With US FDA
Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that it has filed an application with the U.S

Sandoz begins Phase III clinical trial for biosimilar adalimumab
Novartis International AG /Sandoz begins Phase III clinical trial for biosimilar adalimumab. Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Sandoz receives first approval for AirFluSal® Forspiro®
Novartis International AG /Sandoz receives first approval for AirFluSal® Forspiro®. Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

SnackHealthy Announces China Launch of O Organics Dairy Products
SnackHealthy, Inc. (OTCBB: SNAX) today announced the Asian roll out of O Organics milk and yogurt products in an exclusive collaboration with Hong Kong-based Sterling Food Solutions Ltd.

Aquinox Pharmaceuticals Commences Phase 2 Clinical Trial of AQX-1125 in Chronic Obstructive Pulmonary Disease
Aquinox Pharmaceuticals Inc. announced today that it has begun dosing patients in a Phase 2 clinical trial of its lead clinical candidate, AQX-1125, a SHIP1 activator, for the treatment of exacerbations of chronic obstructive pulmonary disease (COPD)

Cellceutix Submits Application for IRB Review to Commence Phase 2b Clinical Trial of Novel Antibiotic Brilacidin

Galapagos selects pre-clinical candidate for cystic fibrosis
Novel potentiator shows more activity in pre-clinical studies than market leader Kalydeco® Start of Phase 1 expected before end 2014 Mechelen, Belgium; 16 December 2013 - Galapagos NV (Euronext: GLPG) announced today that it nominated a pre-clinical candidate potentiator for clinical development in its cystic fibrosis (CF) program.

Cellceutix Updates on Current Status of Programs
Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, today updates shareholders on recent developments and future plans. A comprehensive update will be provided to shareholders in mid January 2014.

Aeolus Files Application for New Patent on AEOL 10150
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)

The Medicines Company Acquires Rempex Pharmaceuticals
The Medicines Company (NASDAQ: MDCO) today announced that it has acquired Rempex Pharmaceuticals, Inc., a company with multiple potential new therapies focused on multi-drug resistant gram-negative bacteria.

Galapagos reports positive Phase 1 results for GLPG1205
Mechelen, Belgium; 4 December 2013 - Galapagos NV (Euronext: GLPG) announced today that GLPG1205, a first-in-class molecule for inflammatory disorders, has demonstrated target engagement, a good safety profile, and favorable drug properties in a Phase 1 study.Galapagos is developing GLPG1205 within its alliance with Janssen Pharmaceutica NV.

TNI BioTech, Inc. Subsidiary Granted Certificate of Free Sale by Nicaraguan Minister of Health for Low Dose Naltrexone
TNI BioTech Inc (OTCQB: TNIB) today announced that the Nicaraguan Ministry of Health has granted a certificate of free sale to the company's wholly-owned subsidiary, TNI BioTech International Ltd., for TNI BioTech's Low Dose Naltrexone product (LDN) for the treatment of patients with autoimmune diseases HIV/AIDS, Crohn's Disease, Multiple Sclerosis and certain cancers.

Galapagos announces GSK2586184 JAK1 molecule moves into Phase 2 for ulcerative colitis
Mechelen, Belgium; 27 November 2013 - Galapagos NV (Euronext: GLPG) announced today that GlaxoSmithKline plan to initiate an exploratory Phase 2 study with GSK2586184 (formerly GLPG0778) in patients with ulcerative colitis, a third indication for this investigational molecule, in addition to psoriasis and lupus.

SnackHealthy Launches 100% Organic Gourmet Pork Sausage Line
SnackHealthy, Inc. (OTCBB: SNAX) announced today the launch of its Organic Harvest™ line of gourmet sausages, produced at the largest organic pork farm in North America. The sausages are fully cooked, blended in organic spices, hardwood-smoked in pork casings and processed in San Francisco from 100% organic certified pork. They are available in five dinner and one breakfast packaging.

Great Northern Cattle Company Joins the American Sustainability Project
The American Sustainability Project (http://www.AmericanSustainabilityProject.com), a wholly owned subsidiary of Bill the Butcher, Inc. (OTCQB: BILB) (http://www.billthebutcher.com), today announced its acquisition of privately held Montana Cattle Holdings LLC, dba Great Northern Cattle Company (http://www.GreatNorthernCattle

This Holiday Season Give Something to Help Keep You Living
In the following blog, MMRGlobal's (OTCQB: MMRF) CEO Robert H. "Bob" Lorsch tells the story of a patient who averted surgery with the help of a Personal Health Record (PHR). In this case, he was the patient and the PHR is MyMedicalRecords

Creation of the American Sustainability Project Announced
The American Sustainability Project is a coalition of preeminent thought leaders, food reformers, meat activists, financiers, a retailer and ranchers joined together to support food-forward agriculture by sourcing, producing and delivering the world's healthiest and most progressively raised foods.

Bill the Butcher Unveils New Logo and Website
Bill the Butcher, Inc. (OTCQB: BILB) with 6 "new school" butcher shops in Seattle launched its re-designed website and simultaneously introduced its new logo today. The new design reflects the company mission to "save the world, one steak at a time" with a raised fist and cleaver, an activist's symbol of unity, strength, defiance and resistance

MWI Acquires Assets of Prescription Containers Inc
MWI Veterinary Supply, Inc. ("MWI" or "the Company") (NASDAQ: MWIV) announced today that it has completed the acquisition of substantially all of the assets of Prescription Containers Inc. ("PCI Animal Health") for approximately $17 million

Umbrella Research Initiates Coverage on TNI BioTech
TNI BioTech, Inc. (PINKSHEETS: TNIB), a biotech company combating fatal diseases through the activation and mobilization of the body's immune system using patented immunotherapy, is pleased to announce that Umbrella Research has initiated coverage on TNI Biotech, Inc. The full report is posted on the Company web site at http://www.tnibiotech

Actelion's novel antibiotic cadazolid to move into Phase III clinical development in patients suffering from Clostridium difficile associated diarrhea
Actelion Pharmaceuticals Ltd /Actelion's novel antibiotic cadazolid to move into Phase III clinical development in patients suffering from Clostridium difficile associated diarrhea . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

The Medicines Company Announces Positive Trial Results for Oritavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
The Medicines Company (NASDAQ: MDCO) today announced results for its SOLO-1 Phase 3 clinical trial of oritavancin, which is under investigation for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).

MARKETEXCLUSIVE.COM: SAVING BEES AS A COMMERCIAL ENTERPRISE, THE LAST STAND AGAINST CCD
bs'd

MarketExclusive.com: Saving Bees as a Commercial Enterprise, The Last Stand Against CCD.
 By: Ahmen Jabril

co.don® AG passes next key milestone on its track to European approval.
co.don AG /co.don® AG passes next key milestone on its track to European approval.. Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Theravance Reports Favorable Outcome of FDA Advisory Committee Meeting on VIBATIV(R) (telavancin) for the Treatment of Nosocomial Pneumonia
Theravance, Inc. (NASDAQ: THRX) today announced a favorable outcome of the Anti-Infective Drugs Advisory Committee (AIDAC) of the U.S. Food and Drug Administration (FDA) meeting on VIBATIV® (telavancin) for the treatment of nosocomial pneumonia (NP) due to susceptible isolates of Gram-positive microorganisms.

Boston Eye Doctor Conducts Eye Care Clinical Research
Dr. Steven A. Nielsen, a board-certified Boston eye doctor, is committed to providing the best medical care while maintaining a leadership position in ophthalmology. In order to achieve this mission, Dr. Nielsen is continually involved in eye care clinical research trials that assist in the discovery and delivery of new medicines, therapies, and technology to the eye care community

New Solutions Decrease Risk of Colorectal Surgical Site Infection
A project to reduce colorectal surgical site infections (SSIs) saved more than $3.7 million in costs for 135 avoided SSIs. The two-and-a-half year project included seven hospitals and was directed by the Joint Commission Center for Transforming Healthcare in collaboration with the American College of Surgeons.

Theravance Announces Posting of Briefing Documents for FDA Anti-Infective Drugs Advisory Committee Meeting on VIBATIV(R) (telavancin)
Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has posted on its website briefing documents for the November 29, 2012 Anti-Infective Drugs Advisory Committee (AIDAC) meeting

Galapagos discovers novel class of antibiotics
First candidate antibiotic is effectiveagainst all tested MRSA strains

Basilea Initiates Next Phase 1 Multiple Ascending Dose Study With Antibiotic Bal30072 Active Against Multidrug-Resistant Gram-Negative Bacteria
Basilea Pharmaceutica AG / Basileainitiates next phase 1 multiple ascending dose study with antibioticBAL30072 active against multidrug-resistant Gram-negative bacteria.Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Novartis receives FDA approval for Flucelvax®, the first cell-culture vaccine in US to help protect against seasonal influenza
Novartis International AG /Novartis receives FDA approval for Flucelvax®, the first cell-culture vaccine in US to help protect against seasonal influenza . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Nicox launches AdenoPlus(TM) in the United States
* Innovative device for differential diagnosis of acute conjunctivitis is Nicox's first commercial launch * New visual identity unveiled to present Nicox as a specialty ophthalmic group Nicox S.A

TNI BioTech Inc., and Hubei Qianjiang Pharmaceuticals Co., Ltd., Announce Venture Partnership for the Development of New Drug for Cancer Therapies
TNI BioTech, Inc. (PINKSHEETS: TNIB) and Hubei Qianjiang Pharmaceutical Co., Ltd., a leading Chinese pharmaceutical company, today announced an agreement to co-develop new cancer drugs based on TNI BioTech's patents involving Methionine Enkephalin which when approved will be marketed in China under the brand name IRT-101 and IRT-102.

Nine of Ten Hospital Infection Control Personnel Cite Antibiotic Misuse
The inappropriate use or misuse of antibiotics was reported by 9 of 10 infection control officers and laboratory personnel in a nationwide survey of 218 hospitals. Problems cited include unnecessary antibiotic use and the use of weaker broad-spectrum agents when 'targeted,' bacteria-specific antibiotics would be more effective. The survey was commissioned by MicroPhage, Inc

Odessa Dentist on Using Porcelain Veneers for Tetracycline-Stained Teeth
Many people might not be aware that certain medications can have a significant impact on oral health. Antibiotics such as tetracycline and doxycycline, as well as antihistamines like Benadryl have been known to cause teeth discoloration, particularly for children whose teeth are still developing. There are a number of techniques available for eliminating stains caused by medications. Dr

Dr. Henry "Skip" Lenz, Pharm.D, Joins TNI BioTech, Inc., as Quality Control Officer
TNI BioTech, Inc. (PINKSHEETS: TNIB), a public company operating in the biotech sector, announced today the signing of an agreement with Pharmaceutical Care Consultants of South Florida, d/b/a Skip's Pharmacy. Under the agreement, Dr. Henry "Skip" Lenz and Phil Giordano will join the company as heads of Quality Control and Quality Assurance for TNIB's pharmaceutical plant in Managua, Nicaragua

Delphi Genetics Grants Merck License for the Use of the StabyExpress™ System
Delphi Genetics SA (“Delphi”) has announced a broad licensing agreement with a subsidiary of Merck & Co., Inc., known as MSD outside the United States and Canada, for the use of the StabyExpress™ technology, which allows high yield, cost effective protein expression without the use of antibiotics.

Cancer drugs may also combat antibiotic resistance
Drugs used for cancer treatment may also help in combating antibiotic resistance, a new study has revealed.

Veena Malik promises to let world know before going to sleep next time
Veena Malik has said that the next time she goes to sleep, she will let the whole world know so that nobody panics.

Zoo authorities in Jharkhand prohibit visitors from going near enclosures
Authorities in Ranchi zoo prohibited the visitors from going near the enclosures after bird flu alert was sounded in the state.

Delphi Genetics Announces That All the Bacterial Strains Present in Its Research Kits Are Completely Sequenced
Delphi Genetics announced today during a presentation at the 34th Annual Meeting of the Molecular Biology Society of Japan that it has established the complete chromosome sequence of all the strains sold in the research kits of the company. The complete genome sequencing of the strains of Escherichia coli (E

Key interventions to reduce maternal, newborn and child deaths identified
A three-year study has identified key interventions to reduce maternal, newborn and chills deaths.

Soon, effective liquid solution to make hospitals safer and bacteria free
Scientists have developed an efficient and cost-effective liquid solution that can help fight antibiotic-resistant bacteria and keep more patients safe from life-threatening infections in hospitals.

ContraFect Corporation Completes Successful Pre-IND Meeting With FDA
ContraFect Corporation, the company that is pioneering the use of recombinant proteins for the treatment of drug-resistant bacteria, completed a face-to-face pre-IND (Investigational New Drug) meeting with the FDA on December 9, 2011 to discuss the development plans for CF-301, a biologic antimicrobial therapy for acute bacterial skin and skin structure infections

Five Things Every Consumer Should Know When Comparing Antivirus Software
Now more than ever before, computer users need to take measures to protect themselves online, and choosing the right antivirus software is a key step in defending against cyberthreats.

ImmuCell Presents Mast Out(R) Product Offering at World Animal Health Congress
ImmuCell Corporation (NASDAQ: ICCC) is today presenting its Mast Out® product offering at the World Animal Health Congress at the Intercontinental Hotel in Kansas City, MO. Mast Out is a Nisin-based intramammary infusion product designed to treat subclinical mastitis without a milk discard or meat withhold requirement

Basilea appoints Chief Financial Officer
Basilea Pharmaceutica AG /Basilea appoints Chief Financial Officer. Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement. Basilea Pharmaceutica Ltd. (SIX: BSLN)today announced that Joachim Blatter has been appointed Chief FinancialOfficer(CFO) of Basilea Pharmaceutica International Ltd

Comment on this story

Share